false
0001712762
0001712762
2026-11-19
2026-11-19
0001712762
BIAF:CommonStockParValue0.007PerShareMember
2026-11-19
2026-11-19
0001712762
BIAF:WarrantsToPurchaseCommonStockMember
2026-11-19
2026-11-19
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 19, 2026
bioAffinity
Technologies, Inc.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-41463 |
|
46-5211056 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(I.R.S.
Employer
Identification
Number) |
3300
Nacogdoches Road, Suite 216
San
Antonio, Texas 78217
(Address
of principal executive offices, including zip code)
(210)
698-5334
(Registrant’s
telephone number, including area code)
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| ☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Title
of each class |
|
Trading
Symbols |
|
Name
of each exchange on which registered |
Common
Stock, par value $0.007 per share |
|
BIAF |
|
The
Nasdaq Stock Market LLC
(Nasdaq
Capital Market) |
| |
|
|
|
|
| Warrants to purchase Common
Stock |
|
BIAFW |
|
The
Nasdaq Stock Market LLC
(Nasdaq
Capital Market) |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
8.01. Other Events.
On
November 19, 2026, bioAffinity Technologies, Inc., a Delaware corporation (the “Company”) released a newsletter providing
an overview of certain recent developments.
A
copy of the newsletter is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Forward-Looking
Statements
Certain
statements in the newsletter constitute “forward-looking statements” within the meaning of the federal securities laws. Words
such as “may,” “might,” “will,” “should,” “believe,” “expect,”
“anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,”
“plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are
forward-looking statements. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult
to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied
by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include,
among others, the Company’s ability to successfully commercialize CyPath® Lung, risks related to the regulatory
environment for laboratory developed tests, the Company’s ability to obtain sufficient financing to fund operations and development;
achieve and sustain physician adoption, test utilization and reimbursement; convert distribution access and market interest into orders
and revenue; successfully conduct research and clinical validation and demonstrate safety, efficacy and clinical utility, as applicable;
obtain and maintain any required regulatory authorizations and comply with evolving regulatory requirements; maintain laboratory capacity
and quality; execute collaborations and distribution arrangements; protect and enforce intellectual property; compete effectively;
and the other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and its subsequent
filings with the Securities and Exchange Commission, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking
statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and
conditions. While the Company believes these forward-looking statements are reasonable, readers of the newsletter are cautioned not to
place undue reliance on any forward-looking statements. The information in the newsletter are provided only as of the date of the newsletter,
and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in the newsletter,
except as may be required by applicable securities laws.
Item
9.01. Financial Statements and Exhibits.
Exhibit
Number |
|
Description |
| 99.1 |
|
Company Newsletter, 2nd Edition, Fall / Winter 2026 |
| 104 |
|
Cover Page Interactive
Data File (embedded within the XBRL document) |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K
to be signed on its behalf by the undersigned hereunto duly authorized.
| Date:
November 19, 2026 |
BIOAFFINITY
TECHNOLOGIES, INC. |
| |
|
| |
By: |
/s/
Maria Zannes |
| |
Name: |
Maria Zannes |
| |
Title: |
President and Chief
Executive Officer |
Exhibit 99.1
bioAffinity
Technologies newsletter, 2nd Edition, Fall/Winter 2026
 |
Company
Newsletter
2nd
Edition
Fall/Winter
2026
Nasdaq:
BIAF |
Message
from our CEO

We
look forward to an exciting and productive holiday season at bioAffinity Technologies as we continue to expand the reach and potential
of our innovative technologies. CyPath Lung continues to gain commercial momentum, with growing adoption by physicians and strong
year-over-year growth in test volume. At the same time, we are opening important new opportunities to bring CyPath Lung to more patients,
including our nationwide federal healthcare distribution agreement with AvMEDICAL and our expanding engagement with physicians,
administrators and leaders serving our nation’s veterans.
We
are also advancing the science behind CyPath Lung, including its potential use in the surveillance of lung cancer survivors, and developing
precision diagnostics to characterize lung inflammation in patients with asthma and COPD that may enable physicians to make more
informed treatment choices for individual patients. We also see promising results of our research to advance our therapeutic discoveries
using self-delivering, stabilized siRNA technology to investigate whether skin cancer cells can be targeted while preserving healthy
cutaneous tissue — representing a potentially significant advancement in selective cancer treatment. The asthma/COPD diagnostic
and siRNA therapeutic programs remain in research and development, distinct from the current commercialization of CyPath Lung.
Our
progress is a testament to the commitment and expertise of the bioAffinity team as we continue advancing innovative solutions to support
earlier disease detection, more informed clinical decisions and better patient outcomes. We are excited about the opportunities ahead
and look forward to keeping you informed as we reach new milestones.
Sincerely,
Maria
Zannes
President
and CEO
CyPath
Lung Commercial Expansion Continues
bioAffinity
Technologies reported record testing volume in October. CyPath Lung test unit sales in Q3 doubled year to date over 2025, with solid
gains in physician utilization and recurring orders.
Together,
the 109% increase in test unit sales, 89% increase in ordering physicians and 48% growth in orders from existing physicians indicate
broader physician adoption and increased repeat utilization.

New
Podcast: Physicians Take the Stage to Discuss the Benefits of CyPath Lung
Tune
in to CyPath Lung Connect, our podcast and educational forum series that brings together leaders in pulmonology, oncology,
and lung health to discuss early lung cancer diagnosis, screening guidelines, and clinical applications. Our most recent podcast,
From CT to Sputum: Rethinking Lung Nodule Risk in Veterans, offers greater insight into the challenges veterans face with
disproportionately high rates of lung cancer. |
|

Listen
and follow here |
Expanding
Awareness, Access and Use of CyPath Lung for U.S. Veterans
Lung
cancer weighs heavily on the veteran community. The U.S. Department of Veterans Affairs (VA) reports that approximately 7,700 veterans
are diagnosed with lung cancer each year.
Our
new nationwide federal healthcare partnership with AvMEDICAL provides an important pathway to expand access to CyPath Lung across VA
medical centers and other federal healthcare facilities. In September, bioAffinity and AvMEDICAL introduced CyPath Lung to more than
300 physicians, healthcare professionals and VA leaders at the 2026 NAVREF Annual Conference, advancing awareness of our noninvasive
test and its potential benefits for veterans at risk for lung cancer. The agreement provides an additional channel for access through
the federal healthcare system; access through this channel does not itself represent completed sales.
Advancing
Development of Precision Diagnostics for Asthma and COPD
According
to the CDC, asthma and COPD affect more than 40M Americans and 650M people worldwide. The global therapeutics market for these conditions
was valued at $92B in 2024 and is projected to reach $155B by 2030.
Our
pipeline includes noninvasive diagnostics being developed to potentially help physicians select treatments for asthma and COPD. We’re
combining Pictor’s multiplex technology with bioAffinity’s proprietary flow cytometry+AI platform and selected biomarkers
to investigate whether these technologies could help physicians more precisely manage two of the world’s most common respiratory
diseases. We are working on next-generation diagnostic tests to characterize lung inflammation and detect biologic drug targets in sputum
for asthma and COPD therapies.
Announcing
Newly Issued Patents
| bioAffinity
Technologies is expanding its global patent estate that protects the technology underlying CyPath Lung and its diagnostic platform.
With additional patent protection now in Hong Kong, China and Japan, the Company is strengthening its intellectual property portfolio
of 14 issued and 24 pending diagnostic patents and supporting CyPath Lung’s positioning to enter Asian markets. |
|
 |
Newly
Released Interviews Highlight Growth
From
record CyPath Lung testing and real-world patient cases to new markets for the Company’s platform technology, CEO Maria Zannes
discusses what’s next for bioAffinity Technologies, including increasing sales, meeting the needs of the federal healthcare market,
clinical research and how the Company’s flow cytometry+AI platform is being developed to serve the needs of multi-billion-dollar
markets.

(click on image
or link to play video)
CyPath
Lung Testing Fuels Growth Ambitions
Proactive
Investor News

(click on image
or link to play video)
bioAffinity
Technologies Reports 200% Revenue Growth, Expands Lung Diagnostics Strategy
Proactive
Investor News

(click
on image or link to play video)
bioAffinity
Technologies Advances CyPath Lung Toward Broader Clinical and Federal Healthcare Adoption
The
Market Link
Get
Caught Up on Recent Company News
(click on date to read release)
bioAffinity
continues to deliver a steady stream of Company news, including:
Nov.
11
A
record number of CyPath Lung tests were performed in October 2026, marking the highest monthly testing volume for the Company’s
noninvasive lung cancer test
Nov.
6
Continued
momentum in CyPath Lung commercialization in third quarter 2026
Oct.
15
Our
Chief Medical Officer presents new perspectives on CyPath Lung’s use for cancer risk assessment at CHEST 2026
Oct.
13
Positive
research results spur development of our new test measuring asthma and COPD-related lung inflammation and drug-related receptors
Oct.
9
Announced
$4 million raised in a registered direct financing of common stock and concurrent private placement priced at-the-market under Nasdaq
rules
Oct.
8
Japan
sends notification of its intent to issue patent protection for our noninvasive CyPath Lung and the AI-built algorithm
Oct.
6
Announcing
over 100% growth in CyPath Lung sales through third quarter 2026
Sept.
30
bioAffinity
Technologies joins its distribution partner AvMEDICAL in presenting to physicians and U.S. veterans in Washington, D.C.
Connect
with bioAffinity Technologies
bioaffinitytech.com
| cypathlung.com
This
newsletter may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements
involve risks and uncertainties, and actual results may differ materially from those expressed or implied. For a discussion of risks
and uncertainties, please refer to bioAffinity Technologies’ filings with the Securities and Exchange Commission (SEC).
CyPath®
Lung is a registered trademark of bioAffinity Technologies, Inc.
View
email in browser
bioAffinity
Technologies, Inc. 3300 Nacogdoches Road, Suite 216, San Antonio, Texas 78217 · USA
update
your preferences or unsubscribe